---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-003191"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T04:30:48.485891+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical reports positive in vitro Hemopurifier data for removing extracellular vesicles from cancer plasma

## Summary
- In vitro binding study of Hemopurifier shows removal of extracellular vesicles (EVs) directly from cancer patient plasma.
- Data supports planned Phase 1 trial in solid tumor patients on anti-PD-1 therapies (Keytruda/Opdivo).
- Descriptive statistics from CRO NAMSA confirm EV removal; PD-L1+ EV subset inconclusive due to low counts.
- Next step: submit data to Ethics Committees in Australia and India to initiate Phase 1 oncology studies.

## SEC filing metadata
- accession: 0001683168-24-003191
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316824003191/0001683168-24-003191-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316824003191/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-003191
- JSON: https://secwatch.observer/filing/0001683168-24-003191.json
- Plain text: https://secwatch.observer/filing/0001683168-24-003191.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.